| Ladene J King, MD | |
|
2291 Evelyn Byrd Ave, Harrisonburg, VA 22801-5424 | |
| (540) 434-3831 | |
| Not Available |
| Full Name | Ladene J King |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 18 Years |
| Location | 2291 Evelyn Byrd Ave, Harrisonburg, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053643627 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 200801177 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Rmh Medical Center | Harrisonburg, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-atlantic Womens Care Plc | 8820998156 | 140 |
News Archive
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Even with higher education, women with a body mass index (BMI) of 30-34.9 (obese I) have double the risk of depression compared with women of normal weight and same educational attainment, according to a new study conducted by a sociologist at Rice University.
For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.
Brain School, a new book from Eaton Arrowsmith School's (EAS) founder and director, Howard Eaton, tells the amazing story of how children with learning disabilities such as Dyslexia, Nonverbal Learning Disabilities and ADHD overcame educational obstacles by reorganizing their brains.
› Verified 8 days ago
| Entity Name | Mid-atlantic Womens Care Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699365072 PECOS PAC ID: 8820998156 Enrollment ID: O20040115000607 |
News Archive
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Even with higher education, women with a body mass index (BMI) of 30-34.9 (obese I) have double the risk of depression compared with women of normal weight and same educational attainment, according to a new study conducted by a sociologist at Rice University.
For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.
Brain School, a new book from Eaton Arrowsmith School's (EAS) founder and director, Howard Eaton, tells the amazing story of how children with learning disabilities such as Dyslexia, Nonverbal Learning Disabilities and ADHD overcame educational obstacles by reorganizing their brains.
› Verified 8 days ago
| Entity Name | Harrisonburg Ob Gyn Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942388939 PECOS PAC ID: 5890710065 Enrollment ID: O20051007000176 |
News Archive
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Even with higher education, women with a body mass index (BMI) of 30-34.9 (obese I) have double the risk of depression compared with women of normal weight and same educational attainment, according to a new study conducted by a sociologist at Rice University.
For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.
Brain School, a new book from Eaton Arrowsmith School's (EAS) founder and director, Howard Eaton, tells the amazing story of how children with learning disabilities such as Dyslexia, Nonverbal Learning Disabilities and ADHD overcame educational obstacles by reorganizing their brains.
› Verified 8 days ago
| Entity Name | Mid-atlantic Womens Care Plc |
|---|---|
| Entity Type | Part B Supplier - Mammography Center |
| Entity Identifiers | NPI Number: 1699365072 PECOS PAC ID: 8820998156 Enrollment ID: O20080611000246 |
News Archive
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Even with higher education, women with a body mass index (BMI) of 30-34.9 (obese I) have double the risk of depression compared with women of normal weight and same educational attainment, according to a new study conducted by a sociologist at Rice University.
For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.
Brain School, a new book from Eaton Arrowsmith School's (EAS) founder and director, Howard Eaton, tells the amazing story of how children with learning disabilities such as Dyslexia, Nonverbal Learning Disabilities and ADHD overcame educational obstacles by reorganizing their brains.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ladene J King, MD 2291 Evelyn Byrd Ave, Harrisonburg, VA 22801-5424 Ph: (540) 434-3831 | Ladene J King, MD 2291 Evelyn Byrd Ave, Harrisonburg, VA 22801-5424 Ph: (540) 434-3831 |
News Archive
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Even with higher education, women with a body mass index (BMI) of 30-34.9 (obese I) have double the risk of depression compared with women of normal weight and same educational attainment, according to a new study conducted by a sociologist at Rice University.
For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.
Brain School, a new book from Eaton Arrowsmith School's (EAS) founder and director, Howard Eaton, tells the amazing story of how children with learning disabilities such as Dyslexia, Nonverbal Learning Disabilities and ADHD overcame educational obstacles by reorganizing their brains.
› Verified 8 days ago
Dr. M Catherine Slusher, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2291 Evelyn Byrd Ave, Harrisonburg, VA 22801 Phone: 540-434-3831 Fax: 540-432-0518 | |
Dr. C. Larry Whitten, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2291 Evelyn Byrd Ave, Harrisonburg, VA 22801 Phone: 540-434-3831 Fax: 540-432-0518 | |
Sarah C. Mercer, P.A. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2291 Evelyn Byrd Ave, Harrisonburg, VA 22801 Phone: 540-434-3831 Fax: 540-432-0518 | |
Ms. Jennifer M Visger, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 240 Lucy Dr, Harrisonburg, VA 22801 Phone: 540-438-1314 Fax: 540-438-0797 | |
Nicole M Koiner, CNM Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 240 Lucy Dr, Harrisonburg, VA 22801 Phone: 540-438-1314 Fax: 540-438-0797 | |
Kimberly Ann Greer, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 240 Lucy Dr, Harrisonburg, VA 22801 Phone: 540-438-1314 Fax: 540-438-0797 |